|drug241||Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) Wiki||0.71|
|drug653||COVID19 vaccine Wiki||0.71|
|drug2529||Placebo Vaccine Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.29|
|D018352||Coronavirus Infections NIH||0.23|
There are 2 clinical trials
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.
Description: Incidence of Adverse Events 1 week post immunisationMeasure: Incidence of Adverse Events Time: 1 weeks post immunisation
Description: COVID19 neutralizing antibody titers post immunisationMeasure: COVID19 neutralizing antibody titers Time: 2 weeks post second immunisation
Description: Frequency of COVID19 spike specific T cells 3 weeks post second immunisationMeasure: COVID19 T cell immunogenicity Time: 3 weeks post second immunisation
Description: COVID19 spike specific antibody titers 6 months post second immunisationMeasure: Durability of antibody response Time: 6 months post immunisation
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%. Furthermore, in our preliminary analysis, areas with existing BCG vaccination programs appear to have lower incidence and mortality from COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.
Description: The primary outcome measure is the development of COVID19 infection. We will use the Cox proportional-hazards model to calculate hazard ratios for the development of Covid-19. This will be reported as the proportion of individuals receiving the intervention who are PCR-positive or seroconvert. defined as number of new cases during the 6 month time periodMeasure: Incidence of COVID 19 Infection Time: 6 months
Description: The secondary outcome measure is disease severity calculated using the Covid Severity Scale Scoring of 0 -10. A score of 10 is worse and a score of 0 is best. Disease severity score will be based on the level of care required for individuals who test positive for COVID19 as follows: non-hospital-based care; patient hospitalized but no oxygen required; hospitalized and oxygen required; patient treated in intensive care and/or on mechanical ventilation; patient died. Additional WHO criteria for severity include severe pneumonia, respiratory failure, acute respiratory distress syndrome, sepsis and septic shock.Measure: Disease Severity Time: up to 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports